Tainted Cough Syrup Deaths Expose Gaps in India’s Drug Oversight

More than 20 children in India died this week after taking cough syrup tainted with industrial chemicals, according to health officials, reviving a threat global health agencies say should not recur. Police have arrested the owner of Sresan Pharmaceutical Manufacturer, maker of the Coldrif syrup at the center of the case. India’s drug regulator said Sresan failed to perform required safety testing.

International health authorities have warned about this pattern. The World Health Organization and the U.N. Office on Drugs and Crime report recent poisonings tied to organized substitution schemes that cut costs by replacing pharmaceutical-grade solvents with cheaper industrial liquids. A joint report in July described the trade in used drums: containers that once held propylene glycol are resold online, sometimes refilled with diethylene glycol or ethylene glycol, and presented as compliant inputs. Old labels left on those drums can mislead buyers, especially smaller firms under price pressure. WHO officials said Indian authorities identified one syrup batch in which toxic glycols made up nearly half the volume, far more than a trace impurity.

The danger has surfaced before and across borders. In 2022, at least 66 children died in The Gambia; fatal clusters in Indonesia and Uzbekistan followed within months. The products in those cases were manufactured in India, a major supplier of generic medicines worldwide. WHO analyst Naseem Hudroge said the recurrence across different companies and countries points to a systemwide failure, not a single error.

The toxicology is well established. Many children’s cough syrups dissolve their active ingredients in propylene glycol, a pharmaceutical-grade solvent. Diethylene glycol and ethylene glycol can look similar and mix the same way, but they can cause acute kidney injury. Clinicians often first see children unable to urinate, an early sign that kidneys are failing under the strain of these poisons.

Today’s supply chains heighten the risk. An active ingredient may come from one country, inactive solvents from another, with formulation and packaging in a third and sales on several continents. At each transfer point, falsified documents or bribes can move tainted materials into otherwise legitimate production. When cases are prosecuted, penalties are often modest, weakening deterrence. This does not require advanced chemistry. It exploits weak checks, low-cost substitutions, and paperwork that appears convincing.

India has taken steps since the 2022 deaths. Authorities launched an Online National Drug Licensing System and required extra screening for cough syrup exports. Yet enforcement remains uneven. A study in PLOS Global Public Health this year found India has not fully adopted WHO’s certification system for pharmaceutical products, which is meant to standardize quality documentation. A memo this week from the Drug Controller General acknowledged Sresan failed to test properly, showing how internal controls can break down even when rules exist.

Experts warn the risk is growing with the rise of online drug sales and more dispersed manufacturing. The United States faced a similar tragedy in 1937, when a sulfanilamide elixir mixed with diethylene glycol killed more than 100 people. Public outrage led to the 1938 Food, Drug, and Cosmetic Act, which gave federal regulators stronger authority over safety and labeling. Health economists and patient-safety advocates say India faces a comparable choice now: strengthen enforcement powers, require batch-level testing of incoming solvents, and build cross-border checks that make it harder for adulterated inputs to move undetected.

The mechanics of prevention are concrete. First, verify solvents before they enter a plant. Batch-by-batch testing for diethylene glycol and ethylene glycol can catch the most dangerous substitutions at the gate. Second, tighten oversight of brokers and intermediaries trading used containers and bulk chemicals, with traceable labeling that cannot be reused without detection. Third, raise penalties where fraud causes injury or death, to match the harm and deter repeat offenses. Fourth, improve data-sharing between national regulators so alerts about suspect suppliers travel as fast as the products.

In the near term, the priorities are urgent and practical: trace contaminated batches, alert clinics and families, and remove unsafe products from circulation. Clinicians should be notified of symptoms linked to glycol poisoning and have clear lines to report suspected cases. For families, transparent public notices, naming products, batch numbers, and points of sale, help stop exposure quickly.

The longer task is to repair the points where a mislabeled drum, a forged document, or a skipped test can reach a child’s bedside. India’s role in global medicine makes the stakes higher, not only for patients at home but also for those far beyond its borders. The question now is whether oversight can keep pace with a supply chain that moves faster than the safeguards around it.